reMYND NV, based in Leuven, Belgium, is a biotech company with drug discovery programs in Alzheimer s and Parkinson s disease. reMYND is a privately owned company, founded in 2002 as a spin-off of the University of Leuven. reMYND s unique proprietary models of neurodegeneration have yielded a rich and promising pipeline of lead compounds with potential against neurodegenerative disorders. In addition, reMYND s technology portfolio also includes well-established transgenic Alzheimer mouse models for contract research services to biotech and pharma.